Ecuphar
Ecuphar Veterinaria SLU is a European veterinary pharmaceutical company developing medications, vaccines, diagnostics, and health products for companion animals and livestock. A subsidiary of Animalcare plc, it serves veterinary clinicians across seven European countries via field sales and wholesalers.
- Company typePrivate
- Founded2016
- HeadquartersSant Cugat Del Vallès, Spain
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ecuphar does
Ecuphar Veterinaria SLU is a European veterinary pharmaceutical company of Belgian origin, operating as a wholly-owned subsidiary of Animalcare Group plc, which is publicly listed on the London Stock Exchange. The company develops, manufactures, and commercializes pharmaceutical products, vaccines, diagnostics, and nutraceuticals for companion animals and livestock, with its geographic footprint spanning seven European countries: Belgium, Netherlands, Germany, Ireland, Spain, Portugal, and Italy. The Spanish headquarters is located at C/ Cerdanya 10-12, pl 6, 08173 Sant Cugat del Vallès, Barcelona, with an additional office at C/ Río de Janeiro 60-66, planta 13, 08016 Barcelona. The Iberian and Italian operations were established through the acquisition of ESTEVE VETERINARIA, which retained its full staff and customer base.
The product portfolio is organized around therapeutic categories including antibiotics (ANTIBIOFARM line: CEPHACARE cefalexin, METROCARE metronidazole, DOXYCARE doxycycline), anti-inflammatories (DAXOCOX enflicoxib, CANIDRYL, RHEUMOCAM), wound care (VETERICYN VF Plus with Hypochlorous Acid), diagnostics (LEISCAN ELISA for leishmaniosis), endocrinology (THIAMACARE methimazole, TRILORALE trilostane), vaccines (MAXIVAC, ETADEX rabies), trace minerals (MULTIMIN), and joint supplements (COSEQUIN). Notable technical features include flavored, divisible tablets to support dosing compliance and proprietary formulations such as DAXOCOX as a novel NSAID compound. Beyond products, Ecuphar operates service programs including LeisPro for integrated canine leishmaniosis management (combining LEISCAN diagnostics with LEISGUARD treatment) and an online endocrinology advisory service connecting veterinarians with Dr. Carlos Melián, a specialist in veterinary endocrinology.
The business model is B2B, selling branded veterinary pharmaceutical products primarily to veterinary clinicians treating companion animals (dogs, cats), with secondary reach into livestock producers (cattle, swine, poultry, sheep, goat, equine) and pet owners through veterinary channels. Distribution is executed through a field sales force of regional sales delegates (delegados de zona) who visit clinics directly, supplemented by veterinary zoosanitary wholesalers (Mayoristas de productos zoosanitarios). Pricing is quote-based and not publicly disclosed. Marketing combines direct sales visits, professional event sponsorship (e.g., I JORNADAS DEL DOLOR with Universidad Autónoma de Barcelona), educational webinars on YouTube, and digital press releases via the Sala de Prensa channel.
Ecuphar firmographics
Firmographics- Name
- Ecuphar
- Legal name
- Ecuphar Veterinaria SLU
- Website
- https://ecuphar.es
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Ecuphar Veterinaria SLU is a European veterinary pharmaceutical company developing medications, vaccines, diagnostics, and health products for companion animals and livestock. A subsidiary of Animalcare plc, it serves veterinary clinicians across seven European countries via field sales and wholesalers.
- Ownership category
- akta.pro rank
Ecuphar industry classification
Industry- Product category
- Veterinary Pharmaceuticals
- NAICS
- Veterinary Services (54194)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Antimicrobials & Anti-infectives (HLAMAEAE)
- akta.pro secondary industries
- Veterinary Vaccines (Biologics) (HLAMAEAL), Endocrinology & Metabolic Drugs (e.g., Diabetes, Thyroid) (HLAMAEAG), Dermatology & Allergy Drugs (HLAMAEAH), Veterinary Vaccines (HLAIAEAH)
Keywords
Where Ecuphar is headquartered
LocationHeadquarters
- HQ city
- Sant Cugat Del Vallès
- HQ country
- Spain
- HQ region
- Europe
Offices3 records
Markets served
Ecuphar business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Veterinary Pharmaceutical Products: Sale of branded veterinary pharmaceutical products including antibiotics, anti-inflammatories, analgesics, dermatologicals, ophthalmics, and other specialty veterinary medications. Products are sold under brand names (CEPHACARE, METROCARE, DOXYCARE, DAXOCOX, CANIDRYL, etc.) to veterinarians and through wholesalers.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
Ecuphar product offering
Product offeringCore offering
Ecuphar develops and commercializes veterinary pharmaceutical products, vaccines, diagnostic kits, and wound care solutions for companion animals (dogs, cats) and livestock (cattle, pigs, horses, sheep, goats, poultry). Its portfolio spans antibiotics, anti-inflammatories, endocrinology, cardiology, dermatology, dental care, vaccines, and reproductive hormones. The company also operates integrated service programs such as LEISPRO for canine leishmaniosis and an online endocrinology advisory service for veterinary professionals.
Product overview
Ecuphar is a veterinary pharmaceutical company developing and commercializing medications, vaccines, diagnostics, and health products for companion animals and livestock. The portfolio spans therapeutic areas including antibiotics (ANTIBIOFARM line with CEPHACARE, METROCARE, DOXYCARE), anti-inflammatories (DAXOCOX, RHEUMOCAM), dermatology (VETERICYN VF Plus wound care), endocrinology (THIAMACARE, TRILORALE), cardiovascular (BENAZECARE), vaccines (MAXIVAC, ETADEX), diagnostics (LEISCAN), and dental care. The company also provides the LEISPRO program for leishmaniasis control and an online endocrinology advisory service. Products target multiple species including dogs, cats, cattle, pigs, horses, sheep, goats, and poultry.
Differentiator
Problem solved
Functional benefit
Brands
- ANTIBIOFARM: Antibiotic product line including CEPHACARE (cefalexin), METROCARE (metronidazol), and DOXYCARE (doxiciclina) for dogs and cats
- LEISPRO
- Vetericyn VF Plus
- DAXOCOX
- COSEQUIN
- Asesoría Online en Endocrinología Veterinaria
- Endocrinology Products
Products and services
- CEPHACARE
Companies that use Ecuphar
Customer profileSegments3 records
Ecuphar technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Ecuphar partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Universidad Autónoma de Barcelona (UAB)minorEcuphar served as sponsor for I JORNADAS DEL DOLOR EN PEQUEÑOS ANIMALES (Pain Management in Small Animals Conference) organized by UAB's Hospital Clínic Veterinari. Event held February 14, 2019 featuring expert speakers on pain management from both human and veterinary medicine perspectives. Sponsorship aligns with Ecuphar's pain management product portfolio (DAXOCOX, CANIDRYL).
- ESTEVE VETERINARIAcoreEcuphar acquired ESTEVE VETERINARIA, significantly expanding territorial coverage to include Spain, Portugal, and Italy while reinforcing veterinary identity. Acquisition maintained continuity of service and all ESTEVE VETERINARIA staff were retained.
Scale indicators1 record
Recent moves7 records
Expansion highlights5 records
Ecuphar competitors and assessment
Company assessmentDirect peers
- Animalcare plc: Animalcare plc is the parent company of Ecuphar and operates an overlapping veterinary pharmaceutical portfolio (companion animal pharma, vaccines, diagnostics) across the same European geographies. It is the most directly comparable entity as it consolidates Ecuphar's results and operates in identical product categories with shared group strategy.
- Vetoquinol: Vetoquinol is a French independent veterinary pharmaceutical company with a comparable size, multi-species portfolio (companion animals and livestock), and European commercial footprint. It competes head-to-head with Ecuphar/Animalcare in many of the same therapeutic categories and country markets.
- Virbac: Virbac is a French-listed veterinary pharmaceutical company with a similarly broad companion-animal and livestock portfolio and strong European presence. It is a direct competitor in the antibiotics, dermatology, and parasiticide categories where Ecuphar's ANTIBIOFARM line competes.
- Dechra Pharmaceuticals: Dechra was a UK-listed specialty veterinary pharmaceuticals company (recently acquired by EQRx/Peels) focused on companion animal endocrinology, dermatology, and analgesics — directly overlapping Ecuphar's core therapeutic areas (Thiamacare, Trilorale, DAXOCOX, Vetericyn). Closely comparable mid-cap specialty positioning.
- Ceva Santé Animale: Ceva is a French veterinary pharmaceutical company with European origins and a comparable multi-species portfolio spanning companion animals and livestock. It competes directly in vaccines, anti-infectives, and reproductive management — categories where Ecuphar is also present.
Broad incumbents
- Zoetis: Zoetis is the global market leader in animal health pharmaceuticals, vaccines, diagnostics, and genetics. It competes with Ecuphar across virtually all of Ecuphar's categories but at vastly larger scale, broader geographic reach, and a deeper R&D pipeline. Sets the strategic benchmark for the industry.
- Elanco Animal Health: Elanco is a US-listed global animal health major offering companion-animal therapeutics, vaccines, and parasiticides. It is a broad incumbent competitor to Ecuphar in European veterinary markets, especially in anti-infectives and dermatology where Ecuphar competes.
- Boehringer Ingelheim Animal Health: Boehringer Ingelheim's animal health division is a global top-3 player in veterinary pharmaceuticals and vaccines, including the legacy Merial portfolio. It competes with Ecuphar in vaccines (where MAXIVAC competes), parasiticides, and companion animal therapeutics across European markets.
- MSD Animal Health: MSD Animal Health (Merck) is a global animal health major with a broad companion-animal and livestock portfolio. It competes with Ecuphar across therapeutics, vaccines, and parasiticides, and is particularly strong in European markets where Ecuphar operates.
- Phibro Animal Health: Phibro Animal Health is a US-listed animal health and nutrition company with a portfolio that includes livestock pharmaceuticals and vaccines (similar in scope to Ecuphar's MULTIMIN and production-animal offerings). It is a broader incumbent competing in shared categories, particularly in cattle and livestock segments.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Ecuphar social profiles
Digital presenceEcuphar financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ecuphar leadership team
Management profileNumber of profiles
Ecuphar subsidiaries and ownership
Company hierarchySubsidiaries2 records
Ecuphar funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ecuphar M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ecuphar
What does Ecuphar do?
Ecuphar develops and commercializes veterinary pharmaceutical products, vaccines, diagnostic kits, and wound care solutions for companion animals (dogs, cats) and livestock (cattle, pigs, horses, sheep, goats, poultry). Its portfolio spans antibiotics, anti-inflammatories, endocrinology, cardiology, dermatology, dental care, vaccines, and reproductive hormones. The company also operates integrated service programs such as LEISPRO for canine leishmaniosis and an online endocrinology advisory service for veterinary professionals.
Is Ecuphar a public or private company?
Ecuphar is a private company. It is currently operating.
When was Ecuphar founded?
Ecuphar was founded in 2016. It employs 51 to 100 people.
Where is Ecuphar based?
Ecuphar is headquartered in Sant Cugat Del Vallès, Spain, in the Europe region.
How does Ecuphar make money?
One revenue line is on record: veterinary Pharmaceutical Products.
Who are Ecuphar's main competitors?
Direct peers on record are Animalcare plc, Vetoquinol, Virbac, Dechra Pharmaceuticals and Ceva Santé Animale. Broad incumbents are Zoetis, Elanco Animal Health, Boehringer Ingelheim Animal Health, MSD Animal Health and Phibro Animal Health.
Does Ecuphar have an API?
No public API is recorded for Ecuphar.
What industry is Ecuphar in?
Ecuphar's product category is Veterinary Pharmaceuticals. Its primary akta.pro industry code is HLAMAEAE, Antimicrobials & Anti-infectives, with a secondary code of HLAMAEAL, Veterinary Vaccines (Biologics). Its NAICS code is 54194 and its SIC code is 2834.